Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Summit Therapeu ADR (SMMT)

Summit Therapeu ADR (SMMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,336,368
  • Shares Outstanding, K 737,680
  • Annual Sales, $ 0 K
  • Annual Income, $ -221,320 K
  • EBIT $ -226 M
  • EBITDA $ -226 M
  • 60-Month Beta -1.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 36.40

Options Overview Details

View History
  • Implied Volatility 85.60% ( -6.21%)
  • Historical Volatility 91.13%
  • IV Percentile 7%
  • IV Rank 5.29%
  • IV High 262.57% on 04/09/24
  • IV Low 75.71% on 06/28/24
  • Put/Call Vol Ratio 0.56
  • Today's Volume 294
  • Volume Avg (30-Day) 4,134
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 92,547
  • Open Int (30-Day) 78,704

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.10
  • Number of Estimates 3
  • High Estimate -0.09
  • Low Estimate -0.11
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.55 +23.26%
on 03/10/25
24.18 -15.63%
on 02/21/25
-0.97 (-4.54%)
since 02/14/25
3-Month
16.46 +23.94%
on 01/14/25
25.00 -18.40%
on 01/24/25
+1.83 (+9.85%)
since 12/17/24
52-Week
2.10 +871.43%
on 05/28/24
33.89 -39.81%
on 09/16/24
+15.78 (+341.56%)
since 03/15/24

Most Recent Stories

More News
Why Summit Therapeutics Stock Was Winning This Week

A very bullish analyst move was the news generally responsible for Summit Therapeutics ' (NASDAQ: SMMT) healthy mid-week stock price pop. That upward lift was largely holding as of Friday before market...

SMMT : 20.38 (-1.97%)
This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year

Summit Therapeutics (NASDAQ: SMMT) has been one of the hottest stocks to own over the past 12 months, with its valuation soaring 300% during that stretch. But things have slowed of late and since the start...

SMMT : 20.38 (-1.97%)
PFE : 25.92 (+0.78%)
2025 March Market Cap Showdown: Andy Cross vs. Matt Argersinger

It's time for another Market Cap Game Show. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center . To get started investing, check out our beginner's guide to investing...

GOOGL : 164.39 (-0.66%)
ROKU : 67.36 (-0.62%)
AAPL : 211.43 (-0.96%)
DDD : 2.60 (+0.58%)
DDOG : 102.47 (+0.66%)
JNJ : 163.01 (+0.12%)
RXO : 18.41 (-0.27%)
QXO : 12.92 (+0.78%)
UA : 6.33 (+1.77%)
DUOL : 285.97 (+0.86%)
FICO : 1,834.15 (+1.90%)
SBUX : 97.65 (-0.47%)
Merck Slips 8% in a Month: Should You Buy, Hold or Sell the Stock?

Merck MRK stock has declined 7.8% in the past month — in roughly the span after it announced fourth-quarter 2024 results and provided a disappointing guidance for 2025.On Feb. 4, Merck announced its...

JNJ : 163.01 (+0.12%)
MRK : 94.79 (+1.10%)
SMMT : 20.38 (-1.97%)
MRNA : 34.37 (-0.72%)
Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer

Summit Therapeutics SMMT reported fourth-quarter 2024 loss per share of 8 cents, in line with the Zacks Consensus Estimate. In the year-ago period, the company incurred a loss of 5 cents per share.The...

MRK : 94.79 (+1.10%)
SMMT : 20.38 (-1.97%)
PFE : 25.92 (+0.78%)
Summit Therapeutics’ Retail Chatter Explodes As Pfizer Trial Pact Drowns Out Q4 Letdown

Message volume on Stocktwits jumped 2,500%, with retail traders focusing on Summit’s partnership to evaluate ivonescimab in combination with Pfizer’s antibody-drug conjugates for solid tumors.

VXF : 175.84 (+0.45%)
SMMT : 20.38 (-1.97%)
VTI : 277.64 (+0.23%)
PFE : 25.92 (+0.78%)
IWM : 203.48 (+0.29%)
3 Stocks That Could Trounce the Market in 2025

If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not, you'll need to find stocks that hold the potential to pack more punch.

SMMT : 20.38 (-1.97%)
LLY : 823.46 (+1.23%)
VRTX : 510.29 (+1.09%)
Is Summit Therapeutics a Millionaire Maker?

Few companies in the biotech industry have performed better in the past two years than Summit Therapeutics (NASDAQ: SMMT) . The drugmaker's shares are up by nearly 540%, thanks to excellent clinical progress...

SMMT : 20.38 (-1.97%)
2 Stocks That Could Soar Again in 2025

Many companies in the biotech industry performed well last year. Two in particular stood out: Viking Therapeutics (NASDAQ: VKTX) and Summit Therapeutics (NASDAQ: SMMT) . Both saw their shares more than...

VKTX : 30.20 (-2.23%)
SMMT : 20.38 (-1.97%)
LLY : 823.46 (+1.23%)
Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock?

It can be exciting to buy a stock that has been red hot and to jump on the bandwagon -- but doing so can come with significant risks. At some point, there's a danger that the stock's rally could dissipate,...

SMMT : 20.38 (-1.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 23.76
2nd Resistance Point 22.53
1st Resistance Point 21.66
Last Price 20.38
1st Support Level 19.56
2nd Support Level 18.33
3rd Support Level 17.46

See More

52-Week High 33.89
Fibonacci 61.8% 21.75
Last Price 20.38
Fibonacci 50% 17.99
Fibonacci 38.2% 14.24
52-Week Low 2.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar